Literature DB >> 23897670

World Health Organization-defined classification of myeloproliferative neoplasms: morphological reproducibility and clinical correlations--the Danish experience.

Ann Brinch Madelung1, Henrik Bondo, Inger Stamp, Preben Loevgreen, Signe Ledou Nielsen, Anne Falensteen, Helle Knudsen, Mats Ehinger, Rasmus Dahl-Sørensen, Nana Brochmann Mortensen, Kira Dynnes Svendsen, Theis Lange, Elisabeth Ralfkiaer, Karsten Nielsen, Hans Carl Hasselbalch, Jürgen Thiele.   

Abstract

We examined inter- and intraobserver reproducibility and concordance between histological diagnosis and independently collected clinical findings in a large series of patients with the major subtypes of myeloproliferative neoplasms (MPNs) and controls. Seven hematopathologists reviewed 272 bone marrow biopsies including 43 controls. Diagnoses were determined according to the 2008 criteria of the World Health Organization (WHO). The participants were blinded to all clinical data except patient age. After initial evaluation all hematopathologists participated in a 3-day meeting with a leading clinician chaired by an expert hematopathologists. In cases with lack of consensus on fiber grading (n = 57), a new evaluation was performed. In cases with discordance on morphological diagnosis (n = 129), an additional nonblinded evaluation taking clinical data into consideration was carried out. For remaining cases with a lack of concordance between morphological diagnosis and clinical diagnosis (n = 33), a similar nonblinded evaluation was performed. Consensus on final histological diagnosis and concordance with clinical diagnosis were determined. Blinded histological evaluation resulted in a 53% consensus rate. After re-evaluation of fiber content, consensus was reached in 60% of cases. Adding clinical data increased the histological consensus to 83%. For cases with a histological consensus, we found a concordance of 71% with the clinician's diagnoses. This is the first study to present a larger cohort of MPN patients mimicking the diagnostic challenges that hematopathologists face in their daily practice. The results support the postulates of the WHO that both morphological and clinical findings are essential for a valid diagnosis
Copyright © 2013 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2013        PMID: 23897670     DOI: 10.1002/ajh.23554

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  8 in total

Review 1.  WHO classification of myeloproliferative neoplasms (MPN): A critical update.

Authors:  Hans Michael Kvasnicka
Journal:  Curr Hematol Malig Rep       Date:  2013-12       Impact factor: 3.952

2.  Equivalence of BCSH and WHO diagnostic criteria for ET.

Authors:  C N Harrison; M F McMullin; A R Green; A J Mead
Journal:  Leukemia       Date:  2016-11-29       Impact factor: 11.528

3.  Time for revival of the red blood cell count and red cell mass in the differential diagnosis between essential thrombocythemia and polycythemia vera?

Authors:  Hans Carl Hasselbalch
Journal:  Haematologica       Date:  2019-11       Impact factor: 9.941

4.  Age-Related Macular Degeneration in Patients With Chronic Myeloproliferative Neoplasms.

Authors:  Marie Bak; Torben Lykke Sørensen; Esben Meulengracht Flachs; Ann-Dorthe Zwisler; Knud Juel; Henrik Frederiksen; Hans Carl Hasselbalch
Journal:  JAMA Ophthalmol       Date:  2017-08-01       Impact factor: 7.389

5.  Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteria.

Authors:  H Gisslinger; G Jeryczynski; B Gisslinger; A Wölfler; S Burgstaller; V Buxhofer-Ausch; M Schalling; M-T Krauth; A-I Schiefer; C Kornauth; I Simonitsch-Klupp; C Beham-Schmid; L Müllauer; J Thiele
Journal:  Leukemia       Date:  2015-12-29       Impact factor: 11.528

6.  Response to Harrison et al. 'Clinically relevant differences between BCSH and WHO diagnostic criteria for ET'.

Authors:  H Gisslinger; G Jeryczynski; A Wölfler; C Beham-Schmid; J Thiele
Journal:  Leukemia       Date:  2016-11-29       Impact factor: 11.528

Review 7.  The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion.

Authors:  Tiziano Barbui; Jürgen Thiele; Heinz Gisslinger; Hans Michael Kvasnicka; Alessandro M Vannucchi; Paola Guglielmelli; Attilio Orazi; Ayalew Tefferi
Journal:  Blood Cancer J       Date:  2018-02-09       Impact factor: 11.037

Review 8.  Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis.

Authors:  T Barbui; J Thiele; A M Vannucchi; A Tefferi
Journal:  Blood Cancer J       Date:  2015-08-14       Impact factor: 11.037

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.